Cipla Limited announced on Tuesday that the Drug Controller General of India (DCGI) had granted them Emergency Use Authorization (EUA) for the launch of Molnupiravir, an antiviral drug to treat mild to moderate Covid-19.

Cipla plans to launch Molnupiravir under the brand name Cipmolnu. Molnupiravir is the first oral antiviral to be authorised by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate Covid-19 with a high risk of becoming severe.

Cipla and Merck Sharpe Dohme (MSD) signed a non-exclusive voluntary licencing deal earlier this year to produce and supply Molnupiravir in India and over 100 other low- and middle-income nations (LMICs). A five-month collaborative experiment undertaken by a coalition of companies resulted in regulatory approval.

Cipmolnu 200mg capsules will be available soon at all major pharmacies and Covid treatment centres across the country, according to Cipla. To assure quick availability to this efficient medication across India, the company has  significant manufacturing capacity and a reliable distribution mechanism in place. Molnupiravir is an antiviral that stops numerous RNA viruses from replicating, including SARS-CoV-2. The medicine is used to treat non-hospitalized people with Covid-19 all over the world.

CAIT tells Finance Minister: Defer GST hike on textiles, footwear

Changes in GST law to come into force from January 1

IndiGo, Air France-KLM ink a codeshare agreement